Yasheng Group Reports Financial Results for the Second Quarter, 2022
The original release is unavailable here.
Story so far
Earlier from YaSheng
Later from YaSheng
- Yasheng Group Teams Up with Jove Pharmaceutics In Order to Bring Next Generation Cancer Curing Cell Therapeutics to Market
- Yasheng Group Resumes Plan to Pay Preferred Dividend to Common Shareholders; Raise Capital for our Subsidiary, Jove Pharmaceutics In Order to Bring Next Generation Cancer Curing Cell Therapeutics to M
- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development
- Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders
- Rare Earth Elements Collected from Wastewater Utilizing Cyanobacteria Now Patent Pending
Follow YaSheng into a list and get an email when it puts out news.
Follow YaSheng